Target family: P2X receptors (type: lgic)
Target: P2X3

Ligand: A317491 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.
Published in: Proc Natl Acad Sci USA

Ligand: AF353 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.
Published in: Br J Pharmacol

Ligand: AF-906 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Medicinal chemistry of adenosine, P2Y and P2X receptors.
Published in: Neuropharmacology

Ligand: αβ-meATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.46999979019165 pEC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem

Ligand: BzATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: camlipixant (Synthetic organic)
Interaction type: Antagonist
Action: Non-competitive
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Published in: Pulm Pharmacol Ther

Ligand: camlipixant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Published in: Pulm Pharmacol Ther

Ligand: eliapixant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers.
Published in: Sci Rep

Ligand: filapixant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Patent): 1,3-thiazol-2-yl substituted benzamides

Ligand: gefapixant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: Japan (2022)
Primary target: no
Median affinity: 8.5 pIC50
Reference (Journal): Medicinal chemistry of adenosine, P2Y and P2X receptors.
Published in: Neuropharmacology

Ligand: RO3 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pIC50
Reference (Journal): Purinoceptors as therapeutic targets for lower urinary tract dysfunction.
Published in: Br J Pharmacol

Ligand: spinorphin (Peptide)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 11 pIC50